ReviewNature reviews. Genetics2016
Translating RNA sequencing into clinical diagnostics: opportunities and challenges.
Review in Nature reviews. Genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 426 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
426 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Coupling Exponential Rolling Circle Amplification to Lateral Flow Devices for Point-of-Care Detection of Viral RNA.Angewandte Chemie (International ed. in English) · 2026Article
- GeneSEA Explorer: An R Shiny Tool for Differential Gene Expression Analysis With Shannon's Entropy Aggregation.Biotechnology and bioengineering · 2026Article
- Assessing the impact of parental linear gene normalization on the performance of statistical models for circular RNA differential expression analysis.Briefings in bioinformatics · 2026Article
- Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson's disease: a data-driven approach.NPJ Parkinson's disease · 2026Article
- Mapping the path to clinical implementation of multi-omics.Nature genetics · 2026Review
- RNA Sequencing Technologies in Acute Lymphoblastic Leukemia: A Comparative Technical Review.Current issues in molecular biology · 2026Review
- Machine learning-driven cancer diagnostics with improved robustness and interpretability.Chemical science · 2026Review
- Network-based machine learning to identify biomarkers for systemic lupus erythematosus.BMC biology · 2026Article
- Integrating MRI radiomics and transcriptomics to predict IDH mutation status and prognosis in glioma.Cancer cell international · 2026Article
- Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.Accounts of chemical research · 2026Article
- Large-scale analysis of temporal gene expression variation in peripheral blood.Nature communications · 2026Article
- Poly(A)+ selection limits detection of long and alternatively spliced transcripts compared with rRNA depletion in RNA-Sequencing.BMC genomics · 2026Article
- Transcriptomic and proteomic analysis of osteogenesis imperfecta disease-specific induced pluripotent stem cells.BMC medical genomics · 2026Article
- Gel-free library preparation for next-generation RNA sequencing and small RNA quantification.Communications biology · 2026Article
- An interpretable deep learning biomarker for prognostication and prediction of adjuvant chemotherapy benefit in gastric cancer.NPJ precision oncology · 2026Article
- A knowledge-guided deep learning framework for quantitative nucleic acid testing.Briefings in bioinformatics · 2026Article
- Transformative Applications and Innovations in Next-Generation Sequencing Data Analysis.Journal of applied genetics · 2026Review
- Enzyme-enhanced RNA isolation from biofilm-producing bacteria.Microbiology spectrum · 2026Article
366 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
With the emergence of RNA sequencing (RNA-seq) technologies, RNA-based biomolecules hold expanded promise for their diagnostic, prognostic and therapeutic applicability in various diseases, including cancers and infectious diseases. Detection of gene fusions and differential expression of known disease-causing transcripts by RNA-seq represent some of the most immediate opportunities. However, it is the diversity of RNA species detected through RNA-seq that holds new promise for the multi-faceted clinical applicability of RNA-based measures, including the potential of extracellular RNAs as non-invasive diagnostic indicators of disease. Ongoing efforts towards the establishment of benchmark standards, assay optimization for clinical conditions and demonstration of assay reproducibility are required to expand the clinical utility of RNA-seq.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.